Oxford Biomedica (OXB) is a pioneer and global leader in the development and manufacture of commercial-scale lentiviral vectors (LVV), a critical component of cell and gene therapies. Ongoing investment in manufacturing capacity and R&D is imperative to reap economic returns in this highly innovative and potentially lucrative therapy area, which has witnessed a step up in investment globally. Multiple deals in 2019 included an expansion of its commercial supply agreement with Novartis by
06 Feb 2020
Oxford Biomedica - OxBox investment to aid future growth
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Oxford Biomedica - OxBox investment to aid future growth
Oxford BioMedica plc (OXB:LON) | 201 0 0.0% | Mkt Cap: 201.3m
- Published:
06 Feb 2020 -
Author:
Dr Susie Jana -
Pages:
5
Oxford Biomedica (OXB) is a pioneer and global leader in the development and manufacture of commercial-scale lentiviral vectors (LVV), a critical component of cell and gene therapies. Ongoing investment in manufacturing capacity and R&D is imperative to reap economic returns in this highly innovative and potentially lucrative therapy area, which has witnessed a step up in investment globally. Multiple deals in 2019 included an expansion of its commercial supply agreement with Novartis by